![Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care](https://cdn.cancerletter.com/media/2024/07/04051040/50-27-4x3-1.png)
![Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care](https://cdn.cancerletter.com/media/2024/07/04051040/50-27-4x3-1.png)
Cover Story
JudiciaryNews Analysis
The Supreme Court last week upended one of the underpinnings of administrative law by weakening the authority of federal health agencies to rely on technical expertise as they regulate medical products, issue coverage decisions, and respond to public health crises.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
Drugs & Targets
NCI Trials
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
NCI Trials for July 2024
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access - Robert Gallo named founding director of Microbial Oncology Program at TGH Cancer Institute
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Proposed rule by CMS would expand access to cancer treatment at tribal facilities
- A view from the BMT unit on the day a Russian cruise missile hit Kyiv’s Ohmatdyt hospital
- Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”